Next Article in Journal
Adolescents’ Perceptions of Contraception Access through Pharmacies
Previous Article in Journal
T.E.A.M.S.Work: Leveraging Technicians to Enhance ABM Med Sync in Community Pharmacies
Previous Article in Special Issue
Evaluation of a Pharmacist Led Oral Chemotherapy Clinic: A Pilot Program in the Gastrointestinal Oncology Clinic at an Academic Medical Center
Open AccessReview

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia

1
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC 27514, USA
2
UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27514, USA
*
Author to whom correspondence should be addressed.
K.M.B. and B.M. contributed equally to this work and are co-senior authors.
Pharmacy 2020, 8(2), 52; https://doi.org/10.3390/pharmacy8020052
Received: 1 March 2020 / Revised: 23 March 2020 / Accepted: 24 March 2020 / Published: 27 March 2020
Chronic lymphocytic leukemia (CLL) is a hematologic malignancy that has seen significant advances in care over the last 5 years with the approval of oral agents such as ibrutinib and venetoclax for the treatment of this disease. As such, there has been a substantial shift away from the traditional chemotherapy infusions which have allowed patients greater autonomy with oral cancer therapies. This paradigm shift poses new challenges for the medical team, including drug–drug interactions, adherence counseling, and financial toxicity. Pharmacists are uniquely trained and equipped to help to manage the changing landscape of CLL care. From identifying common medications which may impair ibrutinib clearance to ensuring patients are on the appropriate anti-infective prophylaxis while receiving obinutuzumab, pharmacists can play a vital role in ensuring the highest quality of patient care. Furthermore, additional credentialing of clinical pharmacists in select states allows for independent visits with the pharmacists, allowing for greater involvement, particularly for initiation of venetoclax and management of ibrutinib-induced toxicities. Pharmacists are essential to both expanding and enhancing the care of patients with CLL and should be leveraged to improve patient outcomes whenever possible. View Full-Text
Keywords: CLL; pharmacist; ibrutinib; venetoclax; initiation; toxicity; monitoring; drug–drug interactions CLL; pharmacist; ibrutinib; venetoclax; initiation; toxicity; monitoring; drug–drug interactions
Show Figures

Figure 1

MDPI and ACS Style

Chen, K.Y.; Brunk, K.M.; Patel, B.A.; Stocker, K.J.; Auten, J.J.; Buhlinger, K.M.; Muluneh, B. Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia. Pharmacy 2020, 8, 52.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop